Skip to main content
Equibles
MTNB logo

MTNB · Matinas BioPharma Holdings, Inc. · Metrics

Track MTNB — free

Use MTNB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MTNB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.70 -0.01 (-0.55%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$1.67M
Shares
979,520
Volume · Oct 23 11.29K Avg daily vol (20 sessions) 144.48K

MTNB metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.70
Market cap
$1.67M

Price action

20 metrics
Price change (1W)
-28.2%
Price change (30D)
-32.8%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
37.9
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
144,479
Relative volume
0.1
Average dollar volume
$380,385

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
979,520

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.9
reciprocal yield 107.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-399.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
-2,168.4%
Trailing 12 months
Net margin
-2,093.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$6.67M
Net income (TTM)
−$6.69M
Trailing 12 months
Diluted EPS (TTM)
$-17.25
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$24.07
Stock compensation per diluted share (TTM)
—
Book value per share
$11.31

Growth

11 metrics
Revenue growth YoY
-65.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.9%
Year over year · more shares
Revenue CAGR (3Y)
+90.6%
Revenue CAGR (5Y)
+55.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-371.7%
Return on assets
-196.1%
Debt / equity
0.0
Current ratio
0.8
EBITDA (TTM)
−$6.67M
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$755,000
Latest balance sheet
Cash & equivalents
$761,000
Total assets
$3.41M
Total debt
$6,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.42M
Capital expenditures (TTM)
—
R&D (TTM)
$8.07M
SG&A (TTM)
—
Stock compensation (TTM)
$687,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
25
13F filer change QoQ
-3
Institutional ownership
2.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.6%
Private-fund adviser ownership
1.6%
Active holders' share change QoQ
-7.8%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
5.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1582554 CUSIP 576810402 13F (30d) 2 filings 2 filers Visit website Investor relations